Author | Srdan Verstovsek, MD, PhD | OncLive

Author | Srdan Verstovsek, MD, PhD

Articles

Dr. Verstovsek on the Rationale Behind Treating Myelofibrosis With CPI-0610/Ruxolitinib

July 13, 2020

Video

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

July 01, 2020

Video

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs

February 22, 2019

Video

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

January 31, 2019

Video

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

x